ViiV Healthcare’s investigational broadly neutralising antibody – N6LS – successfully maintains viral suppression in long-acting treatment of HIV

FHS
March 13, 2025
10:18 am

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

L and J-HZ by L&J Bio for Herpes Zoster (Shingles): Likelihood of Approval

L and J-HZ is under clinical development by L&J Bio and currently in Phase I for Herpes Zoster (Shingles).

February 20, 2024

Plants of the Spirit Realm: A Guide to Plants Containing DMT

Throughout history, various plants have been revered for their psychoactive properties, offering humans a gateway to altered states of consciousness and spiritual experiences. Dimethyltryptamine (DMT)

August 1, 2023

Edgewise’s stock surges as heart drug passes early safety test

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.